Mitsubishi UFJ Asset Management Co. Ltd. Acquires 129,035 Shares of Hologic, Inc. (NASDAQ:HOLX)

Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 3.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,403,220 shares of the medical equipment provider's stock after purchasing an additional 129,035 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 1.95% of Hologic worth $322,272,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. General Partner Inc. acquired a new position in shares of Hologic during the fourth quarter worth $26,000. Groupama Asset Managment boosted its holdings in shares of Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock worth $27,000 after buying an additional 2,999 shares in the last quarter. Venturi Wealth Management LLC grew its position in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after buying an additional 261 shares during the period. EverSource Wealth Advisors LLC lifted its position in shares of Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 260 shares during the period. Finally, Smartleaf Asset Management LLC raised its holdings in shares of Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after purchasing an additional 159 shares during the period. Institutional investors and hedge funds own 94.73% of the company's stock.

Remove Ads

Hologic Price Performance

Shares of NASDAQ HOLX traded down $1.00 during trading hours on Friday, reaching $61.32. 1,110,999 shares of the stock traded hands, compared to its average volume of 1,809,690. The company has a market capitalization of $13.76 billion, a P/E ratio of 19.34, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company's 50-day simple moving average is $65.24 and its two-hundred day simple moving average is $73.29. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52-week low of $60.34 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analyst Weigh In

HOLX has been the topic of a number of research reports. Wolfe Research began coverage on Hologic in a research note on Friday, December 13th. They set a "peer perform" rating on the stock. Argus cut shares of Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Morgan Stanley lowered their target price on Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Stephens reissued an "overweight" rating and issued a $84.00 target price on shares of Hologic in a research report on Thursday, February 6th. Finally, Citigroup lowered their price target on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Hologic currently has a consensus rating of "Hold" and an average target price of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.